JP2021534182A5 - - Google Patents
Info
- Publication number
- JP2021534182A5 JP2021534182A5 JP2021507889A JP2021507889A JP2021534182A5 JP 2021534182 A5 JP2021534182 A5 JP 2021534182A5 JP 2021507889 A JP2021507889 A JP 2021507889A JP 2021507889 A JP2021507889 A JP 2021507889A JP 2021534182 A5 JP2021534182 A5 JP 2021534182A5
- Authority
- JP
- Japan
- Prior art keywords
- self
- composition according
- derived
- antigen
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719219P | 2018-08-17 | 2018-08-17 | |
| US62/719,219 | 2018-08-17 | ||
| PCT/EP2019/072052 WO2020035609A2 (en) | 2018-08-17 | 2019-08-16 | Immunogenic compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534182A JP2021534182A (ja) | 2021-12-09 |
| JP2021534182A5 true JP2021534182A5 (enExample) | 2022-08-22 |
Family
ID=67766133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507889A Pending JP2021534182A (ja) | 2018-08-17 | 2019-08-16 | 免疫原性組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12083174B2 (enExample) |
| EP (1) | EP3836963A2 (enExample) |
| JP (1) | JP2021534182A (enExample) |
| CN (1) | CN113164584A (enExample) |
| AU (1) | AU2019321186B2 (enExample) |
| CA (1) | CA3109165A1 (enExample) |
| WO (1) | WO2020035609A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12290556B2 (en) | 2017-12-18 | 2025-05-06 | Intervet Inc. | Swine influenza a virus vaccine |
| CA3171231A1 (en) | 2020-03-09 | 2021-09-16 | Sean Michael Sullivan | Compositions and methods for inducing immune responses |
| CA3173793A1 (en) * | 2020-04-03 | 2021-10-07 | Andrew Ferguson | Infectious disease antigens and vaccines |
| EP4153223A1 (en) * | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| US20230277649A1 (en) * | 2020-06-19 | 2023-09-07 | Intervet Inc. | Swine influenza a virus vaccine comprising two distinct rna replicon particles |
| CN116171150A (zh) | 2020-08-14 | 2023-05-26 | 阿克丘勒斯治疗公司 | 冻干脂质纳米颗粒的方法 |
| KR20230118715A (ko) | 2020-10-14 | 2023-08-11 | 조지 메이슨 리서치 파운데이션 인코포레이티드 | 이온화 가능 지질 및 이의 제조 및 사용 방법 |
| JP2023551982A (ja) * | 2020-12-02 | 2023-12-13 | セキラス インコーポレイテッド | マルチシストロン性ｒｎａワクチン及びその使用 |
| JPWO2022244825A1 (enExample) * | 2021-05-19 | 2022-11-24 | ||
| US20250019745A1 (en) * | 2021-11-29 | 2025-01-16 | Replicate Bioscience, Inc. | Methods of generating self-replicating rna molecules |
| WO2023213378A1 (en) * | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
| KR20250140103A (ko) * | 2023-02-09 | 2025-09-24 | 화이자 인코포레이티드 | 핵산 및 이의 용도 |
| WO2024254461A2 (en) * | 2023-06-07 | 2024-12-12 | Nutech Ventures | Methods and compositions for vaccine development and delivery |
| WO2024261648A1 (en) * | 2023-06-19 | 2024-12-26 | Seqirus Inc. | Multivalent subtype influenza vaccine |
| CN117205309B (zh) * | 2023-11-07 | 2024-02-02 | 今发制药(南京)有限公司 | 一种流感免疫原组合物和制备方法及其用途 |
| WO2025210141A1 (en) * | 2024-04-05 | 2025-10-09 | Boehringer Ingelheim Vetmedica Gmbh | Delivery system useful for topical administration of rna |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| US11291635B2 (en) | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| EP3449910A1 (en) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| BR112013004879A2 (pt) | 2010-08-31 | 2018-04-24 | Novartis Ag | lipossomas pequenos para entrega de rna que codifica imunogénio |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| TR201908635T4 (tr) | 2010-08-31 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler. |
| AU2012280901B2 (en) * | 2011-07-06 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| EP4014966A1 (en) | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| RU2649133C2 (ru) * | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
| SG11201400250UA (en) | 2011-08-31 | 2014-03-28 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| US20140271829A1 (en) * | 2011-10-11 | 2014-09-18 | Anders Lilja | Recombinant self-replicating polycistronic rna molecules |
| WO2014108515A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| WO2015095346A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| PT3083556T (pt) | 2013-12-19 | 2020-03-05 | Novartis Ag | Lípidos e composições lipídicas para a entrega de agentes ativos |
| CN107072946B (zh) | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
| US10022436B2 (en) * | 2016-01-11 | 2018-07-17 | Verndari, Inc. | Microneedle compositions and methods of using same |
| CN106822887A (zh) * | 2017-01-26 | 2017-06-13 | 中国科学院微生物研究所 | 一种流感病毒四价亚单位疫苗及其应用 |
-
2019
- 2019-08-16 CN CN201980068212.4A patent/CN113164584A/zh active Pending
- 2019-08-16 JP JP2021507889A patent/JP2021534182A/ja active Pending
- 2019-08-16 EP EP19758926.0A patent/EP3836963A2/en active Pending
- 2019-08-16 US US17/268,647 patent/US12083174B2/en active Active
- 2019-08-16 WO PCT/EP2019/072052 patent/WO2020035609A2/en not_active Ceased
- 2019-08-16 AU AU2019321186A patent/AU2019321186B2/en active Active
- 2019-08-16 CA CA3109165A patent/CA3109165A1/en active Pending
-
2024
- 2024-08-06 US US18/795,336 patent/US20250064916A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | mRNA vaccines for COVID-19: what, why and how | |
| Lu et al. | The potential neurological effect of the COVID‐19 vaccines: a review | |
| JP2015522580A5 (enExample) | ||
| JP2014520807A5 (enExample) | ||
| JP2014522842A5 (enExample) | ||
| Mehraeen et al. | Vaccines for COVID-19: a systematic review of feasibility and effectiveness | |
| JP2014520806A5 (enExample) | ||
| JP2023551982A5 (enExample) | ||
| Simnani et al. | COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review | |
| EP3888676A1 (en) | Immunogenic combinations | |
| Lee et al. | Influenza viruses: innate immunity and mRNA vaccines | |
| HRP20230226T1 (hr) | Pegilirani liposomi za isporuku rna koja kodira imunogen | |
| JP2016539946A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| KR20200111729A (ko) | 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진 | |
| JP2018514565A5 (enExample) | ||
| JP7403733B2 (ja) | インフルエンザｈａスプリットワクチンの製造方法 | |
| JP2015524802A5 (enExample) | ||
| JP2014519817A5 (enExample) | ||
| US20250339511A1 (en) | Nucleic acid vaccine against monkeypox virus and use thereof | |
| Ftouh et al. | Contribution of nanotechnologies to vaccine development and drug delivery against respiratory viruses | |
| CN112294954B (zh) | 一种禽用佐剂组合物及其制备方法和应用 | |
| Wong et al. | COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine Li-Ann Wong*, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai. | |
| CN101843901A (zh) | 以纳米乳剂为佐剂的流感病毒疫苗及其制备方法 | |
| Wu et al. | Nanovaccines to combat virus‐related diseases |